New Breast Cancer Drug Found to Significantly Lower Risk of Recurrence

A new breast cancer drug has shown positive results in significantly reducing the risk of recurrence, a new study in the New England Journal of Medicine has shown.

Known as PARP inhibitors, this new pharmaceutical treatment blocks cancer cells from repairing themselves, helping the body to kill the cancer cells more easily. The study was found especially effective in women whose breast cancer was caught at earlier stages but were at a high risk of recurrence.

Remarkably, the risk of recurrence or death was lowered by a full 42% in the women in the study receiving the PARP inhibitor cancer drug providing a positive development in combatting what is the second highest cause of cancer death in women in the U.S. each year.